GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » Sale Of Investment

ALZN (Alzamend Neuro) Sale Of Investment : $0.00 Mil (TTM As of Oct. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro Sale Of Investment?

Alzamend Neuro's sale of investment for the three months ended in Oct. 2024 was $0.00 Mil. It means Alzamend Neuro gained $0.00 Mil from selling investments. Alzamend Neuro's sale of investment for the trailing twelve months (TTM) ended in Oct. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Jul. 2024 ), Alzamend Neuro gained the same money from selling investments in Oct. 2024 ($0.00 Mil).


Alzamend Neuro Sale Of Investment Historical Data

The historical data trend for Alzamend Neuro's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro Sale Of Investment Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Sale Of Investment
Get a 7-Day Free Trial - - - - -

Alzamend Neuro Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alzamend Neuro Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzamend Neuro Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzamend Neuro Business Description

Traded in Other Exchanges
N/A
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Executives
Ault Milton C Iii 10 percent owner 11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141
David J Katzoff officer: Chief Operating Officer 201 SHIPYARD WAY, NEWPORT BEACH CA 92663
Stephan Jackman director, officer: Chief Executive Officer C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Lynne Fahey Mcgrath director 28145 CEDAR POINT RD., EASTON MD 21601
Mark Gustafson director 10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9
William B. Horne director C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626
Henry Carl Nisser director, officer: Exec VP and General Counsel 100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017
Kenneth S Cragun officer: SVP of Finance 3775 CHIPPEWA CIRCLE, CORONA CA 92881
Jeffrey Oram director 15 ORCHARD STREET, MENDHAM NJ 07945
Escalona Lien officer: Chief Financial Officer C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Andrew H. Woo director 2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404

Alzamend Neuro Headlines

From GuruFocus

Alzamend Neuro Announces Reverse Stock Split

By Business Wire 07-12-2024